Loading organizations...
§ Private Profile · Oslo, Norway
Biotech company developing bioengineered tissue therapeutics using microfluidics and hydrogel technology for end-stage liver disease.
ClexBio is an Oslo, Norway-based biotechnology company that develops tissue engineering and single-cell solutions by combining advanced microfluidics with its proprietary hydrogel technology. The enterprise focuses on creating bioengineered tissue therapeutics, utilizing structured delivery systems that enable cells to survive, engraft, and scale into functional vascularized tissues. Initially targeting hepatocyte-based liver products for the treatment of end-stage liver disease, the firm is currently expanding its preclinical data for a broader, multi-indication therapeutic platform. In 2021, the organization joined the Nordic Mentor Network for Entrepreneurship, and it subsequently secured strategic investments in late 2024 to fund its expansion into the United States and a planned corporate relocation to Zurich. Backed by institutional investors including GG 1978, Giammaria Giuliani, and the EQT Foundation, the preclinical venture was co-founded by Armend Håti and Manuel Schweikle.
ClexBio has raised $2.2M across 1 funding round.
ClexBio has raised $2.2M in total across 1 funding round.
ClexBio has raised $2.2M in total across 1 funding round.
ClexBio's investors include Centre for Digital Life Norway, Innovation Norway, Research Council of Norway, UK Engineering and Physical Sciences Research Council.
ClexBio has raised $2.2M across 1 funding round. Most recently, it raised $2.2M Seed in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 20, 2021 | $2.2M Seed | — | Centre For Digital Life Norway, Innovation Norway, Research Council OF Norway, UK Engineering And Physical Sciences Research Council | Announced |
ClexBio is a biotechnology company specializing in next-generation tissue therapeutics aimed at addressing chronic diseases through regenerative medicine. Their core product is the VivoSet™ technology platform, which enables scalable, high-throughput generation of fully vascularized, lab-grown therapeutic tissues that mimic human anatomy and function. These tissues are designed to restore lost cell and organ function permanently by integrating with the host’s vasculature and providing a thriving cellular microenvironment without artificial materials, reducing immune rejection risks. ClexBio primarily serves patients with chronic conditions such as advanced liver disease, Type I diabetes, and heart disease, offering new therapeutic options where traditional treatments fall short. The company is in the preclinical stage but shows strong growth momentum supported by investments from firms like EQT Foundation, which is helping accelerate product development and preclinical studies[1][2][3].
ClexBio was founded by Armend Håti, who brings expertise in biotechnology and regenerative medicine. The idea emerged from the need to overcome the limitations of current cell and tissue therapies, particularly for chronic diseases with high unmet medical needs such as liver failure. Early traction includes the development of the VivoSet™ platform and a prototype bioreactor in collaboration with CSEM, a Swiss R&D center, to manufacture tissue-engineered vein implants. This milestone demonstrated the ability to produce functional human tissue grafts in a closed, automated system suitable for clinical and commercial scale-up, marking a pivotal moment in their journey toward in-human studies[2][3][4].
ClexBio is riding the wave of regenerative medicine and tissue engineering, a rapidly growing field driven by the increasing burden of chronic diseases and the limitations of conventional therapies. The timing is critical as advances in cell biology, biomaterials, and biomanufacturing converge to enable scalable production of functional tissues. Market forces such as aging populations, rising chronic disease prevalence, and healthcare system strain favor innovative, durable solutions like those ClexBio offers. By pioneering scalable tissue therapeutics with strong integration potential, ClexBio influences the broader ecosystem by pushing the boundaries of what regenerative medicine can achieve, potentially reducing the need for organ transplants and long-term drug therapies[1][2][3].
Looking ahead, ClexBio is positioned to advance into clinical trials, leveraging its scalable manufacturing platform to bring tissue therapeutics closer to patients. Trends shaping their journey include increasing regulatory acceptance of cell and tissue therapies, technological improvements in bioreactor automation, and growing investment in biotech innovation. Their influence may expand beyond liver disease to other chronic conditions, potentially transforming regenerative medicine into a mainstream therapeutic approach. Continued collaboration with research institutions and strategic investors like EQT Foundation will be crucial for accelerating development and commercialization. ClexBio’s vision of a paradigm shift in medicine through engineered tissues aligns with the urgent global need for more effective, long-lasting treatments for chronic diseases[2][4][5].